Finding the right tests…
Emergency services available 24 x 7
Emergency services available 24 x 7
Finding the right tests…
ELISA
ANCA-PR3 looks for antibodies against proteinase 3, an enzyme found inside neutrophils, and is the antibody most closely tied to granulomatosis with polyangiitis, a vasculitis that classically affects the sinuses, airways, and lungs before it reaches the kidneys. Doctors order it when a patient has persistent sinus disease that doesn't respond to usual treatment, unexplained lung nodules, coughing blood, or nosebleeds alongside joint pain and fatigue. PR3-ANCA disease tends to involve more organs outside the kidney and is watched more closely for relapse than the related MPO antibody, since studies following patients over years show a meaningfully higher rate of disease coming back after treatment.
The test detects and, when positive, typically quantifies antibodies against proteinase 3 by immunoassay, and it is sometimes confirmed with a separate immunofluorescence pattern known as c-ANCA. A positive PR3-ANCA supports a diagnosis of ANCA-associated vasculitis, most often granulomatosis with polyangiitis, which classically involves granulomatous inflammation in the respiratory tract in addition to smaller blood vessels. The result guides how closely a doctor screens the sinuses, lungs, and kidneys, and it factors into decisions about how long to continue treatment, since PR3-positive disease relapses more often than MPO-positive disease.
Granulomatosis with polyangiitis, the condition PR3-ANCA is most linked to, tends to involve more organs outside the kidney than microscopic polyangiitis, the disease more typical of MPO-ANCA. Sinus disease, lung nodules, and airway narrowing are more characteristic of PR3-positive disease, alongside the kidney involvement both conditions can eventually cause.
Long-term studies following ANCA-associated vasculitis patients report a relapse rate near 50 percent within five years for people who are PR3-ANCA positive, notably higher than the 20 to 30 percent seen in MPO-ANCA positive patients. Because of this, a PR3-positive diagnosis often leads to a longer course of maintenance treatment and more frequent follow-up than an MPO-positive one.
Genetic studies have linked PR3-ANCA more closely with the HLA-DP gene region, distinct from the HLA-DQ association seen with MPO-ANCA. This distinction supports treating PR3- and MPO-associated vasculitis as related but separate conditions, each carrying its own pattern of organ involvement and relapse risk, rather than one disease defined by a single antibody test.
It most classically involves the sinuses, airways, and lungs, though it can also affect the kidneys as the disease progresses. This wider organ involvement is one of the features that distinguishes it from MPO-ANCA disease.
The two antibodies target different enzymes inside neutrophils and are linked to different vasculitis patterns - PR3 more with sinus and lung disease, MPO more with kidney-limited disease. Doctors often test for both since a person is usually positive for only one.
Studies following patients over years have found that people who are PR3-ANCA positive have a meaningfully higher chance of the disease returning after treatment compared with MPO-ANCA positive patients. This affects how long maintenance treatment continues.
This page is general information about the test, not medical advice. Your own report's reference ranges apply — please discuss your results with your doctor.
A negative result falls below the cutoff set by that lab's specific immunoassay. Ranges vary by lab, so use the reference value printed on your own report.
c-ANCA describes the staining pattern seen under immunofluorescence, and PR3-ANCA is the specific antibody usually responsible for that pattern. Many labs test for the PR3 antibody directly instead of relying only on the pattern.
There's no fixed fasting rule tied to this specific test. Ask your doctor or the centre when you book, since instructions can change if other tests are drawn at the same time.
It's uncommon but possible, and a positive result without matching symptoms is usually followed up rather than treated immediately. Your doctor considers your full clinical picture, sometimes alongside imaging or a biopsy, before starting treatment.